No income investor buys shares of a dividend-paying company expecting that it will suspend its distributions at some point. Quite the contrary, dividend investors want those payouts to keep going and growing for as long as possible -- preferably forever. Unfortunately, many companies will, at some point, have to resort to dividend cuts because of business challenges.
However, in my view, Visa (NYSE: V) and Novartis (NYSE: NVS) look likely to avoid this future, and both are worth investing in and holding onto for good. Let's look at both.
1. Visa
Visa, a leading payment network company, has an excellent dividend track record. It has been paying dividends since 2008 when it went public, and it has increased its payouts every year.
Visa can afford it: It generates consistent and growing revenue, earnings, and free cash flow. Its payment network helps facilitate hundreds of millions of credit card transactions daily, with the company taking a small cut of each. Its business also generates excellent margins. The company's gross margins are generally around 80%, while it typically nets about $0.50 for every dollar in revenue.
V Gross Profit Margin (Quarterly) data by YCharts.
That degree of profitability is rare for a company as large as Visa, but it's not an accident. Visa's payment network is already in place. Additional transactions add little in the way of costs, resulting in strong margins.
Further, Visa's ecosystem of banks, consumers who carry credit cards bearing its logo, and businesses that accept those cards for payment is such that it becomes more valuable as it grows, making it a natural example of the network effect. Visa has few direct competitors of note to speak of, nor is the company letting the increased digitization of payments challenge its dominance.
The company has been adapting its business to the changing nature of the financial industry. Lastly, it should still have plenty of growth opportunities, with trillions of dollars worth of transactions still being performed outside the scope of the kinds that Visa's network supports. The ongoing displacement of cash and digitization of payments will provide a powerful long-term tailwind to the company.
Visa is well-positioned to deliver excellent returns and consistent dividend growth throughout it all.
2. Novartis
There is always a high demand for vital pharmaceuticals of the types that Novartis offers. It has been in the drug-making business for a long time, and its portfolio includes many "blockbusters" -- drugs that generate more than $1 billion in annual sales. It routinely develops newer products to replace those losing sales to patent expirations and competition.
Most important for investors, its financial results are generally strong, and the third quarter hewed to that pattern. Revenue increased by 9% year over year to $12.8 billion, while earnings per share rose 18% to $2.06. Its free cash flow also rose 18% to about $6 billion. It should be able to keep delivering similar results for a while despite recent changes to its business.
The company spun off its generic and biosimilar unit as Sandoz just over a year ago, and has slimmed down its clinical-stage pipeline by 40% in recent years. That gives the business less diversification. However, it also prevents the company from spreading its resources too thin, and positions it to instead focus on higher-growth opportunities.
Even after whittling down its pipeline, Novartis still boasts several dozen programs in development. The company should be able to continue winning enough new regulatory approvals and label expansions to keep its revenue and earnings moving in the right direction for a long time. Novartis has also been paying and raising its dividends for a while. The company's streak of payout increases stands at 27 consecutive years -- an impressive track record.
At the current share price, Novartis has a competitive dividend yield of 3.65% -- the S&P 500's average yield is only 1.32%. The drugmaker is committed to rewarding its shareholders in this way, and that's not likely to change anytime soon. Novartis is a great dividend stock to buy and hold for good.
Should you invest $1,000 in Visa right now?
Before you buy stock in Visa, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Visa wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $847,211!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of November 25, 2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
